Intersect ENT, Inc
XENT
XENT was delisted on the 12th of May, 2022.
157 hedge funds and large institutions have $817M invested in Intersect ENT, Inc in 2017 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 54 increasing their positions, 52 reducing their positions, and 12 closing their positions.
733% more call options, than puts
Call options by funds: $5.8M | Put options by funds: $696K
142% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 12
12% more funds holding
Funds holding: 140 → 157 (+17)
4% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 52
3% more capital invested
Capital invested by funds: $792M → $817M (+$25.3M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$15.3M |
| 2 |
Jennison Associates
New York
|
+$11.2M |
| 3 |
DM
Deerfield Management
New York
|
+$7.75M |
| 4 |
TA
Teachers Advisors
New York
|
+$6.66M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$33.6M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$23.9M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$3.99M |
| 4 |
CM
Castleark Management
Chicago,
Illinois
|
-$3.52M |
| 5 |
PVI
Pura Vida Investments
New York
|
-$3M |
XENT Hedge Fund Activity: Q4 2017 in Review
157 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Intersect ENT, Inc (XENT) for Q4 2017, worth a combined $817M — up 3.2% from $792M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new XENT positions and 12 closed out — a net gain of 17 holders — while 54 added to existing stakes and 52 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $15.3M. The largest seller was Fidelity Investments, cutting an estimated $33.6M.
- 157 institutional investors held Intersect ENT, Inc (XENT) as of Q4 2017, up from 140 in Q3 2017.
- Funds reported $817M of Intersect ENT, Inc stock for Q4 2017, up 3.2% quarter-over-quarter.
- 29 funds opened new Intersect ENT, Inc positions in Q4 2017 and 12 closed out, a net change of +17 holders.
- The largest Intersect ENT, Inc buyer in Q4 2017 was Point72 Asset Management, an estimated $15.3M added.
- The largest Intersect ENT, Inc seller in Q4 2017 was Fidelity Investments, an estimated $33.6M sold.
Based on aggregated 13F filings for Q4 2017.